Zyprexa (Eli Lilly) Drug Overview & Outlook 2017/18-2026 - ResearchAndMarkets.com

DUBLIN--()--The "Drug Overview: Zyprexa" report has been added to ResearchAndMarkets.com's offering.

Zyprexa (Eli Lilly) contains the atypical antipsychotic olanzapine, which acts as an antagonist at the D2 and 5-HT2A receptors. Zyprexa was initially launched in September 1996 for the treatment of schizophrenia. Eli Lilly subsequently pursued development in bipolar disorder and received the first approval for Zyprexa as a monotherapy in the treatment of manic and mixed episodes in 2000.

Key Topics Covered

  1. Drug Overview
  2. Product Profiles
  3. Zyprexa: Bipolar Disorder
  4. Zyprexa: Schizophrenia

List of Figures

Figure 1: Zyprexa for bipolar disorder - SWOT analysis

Figure 2: Drug assessment summary for Zyprexa in bipolar disorder

Figure 3: Drug assessment summary for Zyprexa in bipolar disorder

Figure 4: Zyprexa for schizophrenia - SWOT analysis

Figure 5: Drug assessment summary of Zyprexa for schizophrenia

Figure 6: Drug assessment summary of Zyprexa for schizophrenia

Figure 7: Zyprexa sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: Zyprexa bipolar disorder indication approvals

Table 2: Zyprexa drug profile

Table 3: Overview of key pivotal trial data for Zyprexa in bipolar disorder

Table 4: Adverse reactions reported in =5% of patients in six-week clinical trials of Zyprexa as an adjunct to lithium or valproate in adult bipolar disorder (manic/mixed episodes)

Table 5: Key side effects reported in clinical trials of Zyprexa in bipolar disorder

Table 6: Zyprexa drug profile

Table 7: Zyprexa pivotal trial data in schizophrenia

Table 8: Zyprexa sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017-26

For more information about this report visit https://www.researchandmarkets.com/research/hhmvmg/zyprexa_eli?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Mental Disorders Drugs, Schizophrenia Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Mental Disorders Drugs, Schizophrenia Drugs